Clinical trial
High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating…
NCT00003353 · Eastern Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00003353 |
|---|---|
| Title | High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis |
| Official title | A Phase II Study of High-Dose Melphalan With Hematopoietic Stem Cell Reconstitution for Patients With Primary Systemic Amyloidosis |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Biological, Drug, Procedure |
| Interventions | filgrastim, melphalan, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation |
| Start date | Nov 16, 1998 |
| Primary completion | Dec 1, 2002 |
| First posted | Sep 13, 2004 |
| Last update posted | Jun 22, 2023 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: